Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) on Wednesday announced that, through its subsidiary Lexaria CanPharm ULC, it has entered a definitive 5-year agreement to provide Lexaria’s patented DehydraTECH(TM) technology to a private California-based cannabis company. Under the agreement the cannabis company will utilize the technology in certain cannabis-based beverages to be produced and sold in the states of California and Nevada. DehydraTECH-enabled beverages are protected under Lexaria’s many existing US-granted patents and may include any combination of ready-to-drink beverages such as non-alcoholic beers, wines and spirits; cold or hot coffee or teas, sports drinks and much more. In addition, Lexaria this morning announced the addition of Dr. Dwayne Godwin, Dr. Terry D. Blumenthal, Dr. Matthew Fraser and Dr. Carla Lema Tome to its Scientific Advisory Board. Each of the new appointees will contribute support, advice and recommendations related to the company’s scientific research and product development. “Lexaria Bioscience Corp. is very pleased to welcome these accomplished experts to our Advisory Board, who can provide critical scientific guidance to Lexaria’s ongoing and future R&D programs,” Lexaria CEO Chris Bunka said in the news release. “Lexaria is building towards becoming one of the world’s leaders in drug delivery technology and our most recent Advisors can assist in achieving that goal.”
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates, more rapid delivery to the bloodstream, and important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000
For more information please visit https://www.CannabisNewsWire.com
Do you have a questions or are you interested in working with CNW? Ask our Editor